Lumos Diagnostics Holdings Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LDXHF research report →
About the company
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms.
- CEO
- Douglas Ward
- IPO
- 2021
- Employees
- 15
- HQ
- Melbourne, CA, AU
Price Chart
- Market Cap
- $61.07M
- P/E
- -5.98
- P/S
- 4.51
- P/B
- 10.76
- EV/EBITDA
- -6.95
- Div Yield
- 0.00%
- Gross Margin
- 2.96%
- Op Margin
- -81.50%
- Net Margin
- -75.84%
- ROE
- -164.12%
- ROIC
- -85.80%
- Revenue
- $12.50M · 12.30%
- Net Income
- $-7,183,000 · 16.40%
- EPS
- $-0.01 · 39.08%
- Op Income
- $-7,842,000
- FCF YoY
- -1206.96%
- 52W High
- $0.24
- 52W Low
- $0.04
- 50D MA
- $0.09
- 200D MA
- $0.15
- Beta
- 0.55
- Avg Volume
- 56.83K
Get TickerSpark's AI analysis on LDXHF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our LDXHF coverage
Recent articles, reports, and earnings notes.
No research on LDXHF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LDXHF report →Similar companies
Peers in the same neighborhood.